Biotronik has received U.S. Food and Drug Administration (FDA) approval for its Solia CSP S pacing lead, growing access to a solution for Left Bundle Branch Area Pacing (LBBAP).

Solia CSP S is touted as the first pacing lead to combine a stylet-driven lead platform with a fixed helix, specifically designed for LBBAP procedures. The lead’s optimized helix, enhanced steerability, and simplified handling are engineered to reduce prep time while improving procedural efficiency and ease of delivery, the company said.

“FDA approval for the Solia CSP S pacing lead represents an important step forward in the continued advancement of physiologic pacing,” said Larry Chinitz, MD, Director of Cardiac Electrophysiology at NYU Langone’s Heart Rhythm Center, Co-Director of NYU Langone Heart and principal Investigator of the BIO-CONDUCT study. “Investigator experiences from the BIO-CONDUCT IDE trial highlight the value of a product specifically engineered for LBBAP.”

“The Solia CSP S pacing lead provides a purpose-built solution long overdue for conduction system pacing,” added Christopher Liu, MD, Medical Director of Cardiac Electrophysiology Services for the New York-Presbyterian – Weill Cornell Network. “With the combination of a stylet-driven platform and fixed helix, Solia CSP S is a new generation lead that can now be used to achieve physiologic pacing for our patients.”

Doctors and healthcare professionals can experience the new pacing lead at this year’s Heart Rhythm Society Annual Scientific Sessions. Attendees will experience live demonstrations, hands-on training, and expert-led discussions on LBBAP and physiologic pacing.

“With FDA approval, we reinforce our dedication to continued innovation in the critical field of CSP,” said Ryan Walters, president of Biotronik. “Solia CSP S reflects our commitment to advancing physiologic pacing and equipping clinicians with solutions that enhance patient outcomes.”

Earlier this month, the company formed a new partnership with MiCare Path to deliver a comprehensive remote physiologic monitoring (RPM) program for cardiology practices.